OTTOBOCK SE & CO. KGAA

Their core work

Ottobock is a global leader in prosthetics, orthotics, and human mobility solutions, headquartered in Duderstadt, Germany. In H2020 projects, they serve as the industrial end-user and validation partner for advanced prosthetic limbs, exoskeletons, and assistive robotics — bringing decades of product development experience to translate academic research into real medical devices. Their core contribution is bridging the gap between neuromechanical research and commercially viable assistive technologies, particularly in upper and lower limb prosthesis control systems.

What they specialise in

How they've shifted over time

In 2015–2018, Ottobock focused on hardware-centric challenges: advanced manufacturing (Symbionica), spinal exoskeletons (SPEXOR), and intuitive upper-limb prosthesis control with direct end-user training and testing (INPUT). From 2017 onward, their focus shifted toward software, simulation, and societal integration — neuromechanical modelling for bionic legs (SimBionics), human-robot collaboration (An.Dy), inclusive robotics governance (INBOTS), and responsible innovation in smart health (LIV.IN). The trajectory shows a clear move from mechanical prosthetics toward intelligent, sensor-driven assistive systems embedded in broader societal contexts.

Ottobock is moving from passive/mechanical prosthetic components toward AI-driven, sensor-rich bionic systems with neuromechanical simulation — expect future work in smart prosthetics, digital twins for rehabilitation, and human-robot interaction.

How they like to work

Ottobock operates almost exclusively as a participant (6 of 7 projects), stepping into the coordinator role only once — for SimBionics, a Marie Curie training network closely aligned with their core product line. With 69 unique partners across 18 countries, they function as a high-value industrial partner that research consortia seek out for real-world validation, end-user testing, and clinical deployment expertise. Their wide partner network and low repeat-collaboration pattern suggest they are a sought-after industry name that lends credibility and market access to academic-led proposals.

Ottobock has collaborated with 69 distinct partners across 18 countries, reflecting a broad pan-European network. Their partnerships span universities, robotics labs, and rehabilitation centers, with no visible geographic concentration beyond a natural anchor in Western Europe.

What sets them apart

Ottobock is one of very few global prosthetics manufacturers actively embedded in EU research consortia, which means they offer something most academic partners cannot: a direct path from prototype to commercial medical device. Their participation signals to reviewers and partners that the research has genuine market pull and a credible route to patient impact. For consortium builders, having Ottobock on board adds immediate industrial credibility in any proposal involving assistive technologies, rehabilitation, or wearable robotics.

Highlights from their portfolio

• SimBionics
  Their only coordinated project — a Marie Curie training network on neuromechanical simulation for bionic legs, signaling this as their strategic R&D priority.
• INPUT
  Largest single EC contribution (EUR 469,962) with explicit end-user verification tests for intuitive arm prosthesis control — showcasing their clinical validation capability.
• SPEXOR
  Highest funded project (EUR 521,250) developing a spinal exoskeletal robot for occupational health, extending Ottobock beyond prosthetics into workplace ergonomics.